Natera Inc (NTRA) Expected to Announce Quarterly Sales of $66.51 Million
Equities analysts forecast that Natera Inc (NASDAQ:NTRA) will announce $66.51 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Natera’s earnings. The lowest sales estimate is $65.10 million and the highest is $69.35 million. Natera reported sales of $53.80 million in the same quarter last year, which indicates a positive year over year growth rate of 23.6%. The company is scheduled to report its next quarterly earnings results on Tuesday, March 12th.
On average, analysts expect that Natera will report full-year sales of $258.11 million for the current financial year, with estimates ranging from $255.80 million to $261.79 million. For the next fiscal year, analysts forecast that the company will post sales of $314.34 million, with estimates ranging from $293.33 million to $339.87 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Natera.
Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.03). Natera had a negative return on equity of 2,569.52% and a negative net margin of 58.00%. The company had revenue of $65.30 million for the quarter, compared to analysts’ expectations of $66.42 million. During the same quarter in the previous year, the business earned ($0.51) EPS. The company’s revenue for the quarter was up 16.8% on a year-over-year basis.
In related news, COO Steven Leonard Chapman sold 45,000 shares of Natera stock in a transaction that occurred on Tuesday, September 11th. The shares were sold at an average price of $25.16, for a total value of $1,132,200.00. Following the completion of the transaction, the chief operating officer now directly owns 16,628 shares in the company, valued at approximately $418,360.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jonathan Sheena sold 166,667 shares of Natera stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $24.27, for a total transaction of $4,045,008.09. Following the completion of the transaction, the insider now owns 481,975 shares of the company’s stock, valued at $11,697,533.25. The disclosure for this sale can be found here. Insiders sold a total of 2,014,988 shares of company stock valued at $48,674,710 over the last quarter. 13.18% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in NTRA. FMR LLC purchased a new position in Natera in the 3rd quarter valued at approximately $59,599,000. Fred Alger Management Inc. purchased a new position in Natera in the 2nd quarter valued at approximately $33,271,000. Jennison Associates LLC grew its stake in Natera by 39.1% in the 3rd quarter. Jennison Associates LLC now owns 3,641,848 shares of the medical research company’s stock valued at $87,186,000 after buying an additional 1,024,225 shares in the last quarter. Renaissance Technologies LLC grew its stake in Natera by 92.9% in the 3rd quarter. Renaissance Technologies LLC now owns 1,528,400 shares of the medical research company’s stock valued at $36,590,000 after buying an additional 736,000 shares in the last quarter. Finally, BlackRock Inc. grew its stake in Natera by 33.5% in the 3rd quarter. BlackRock Inc. now owns 2,785,208 shares of the medical research company’s stock valued at $66,679,000 after buying an additional 698,379 shares in the last quarter. Institutional investors and hedge funds own 68.11% of the company’s stock.
Shares of NTRA stock traded up $0.66 during trading hours on Monday, hitting $16.08. 573,430 shares of the company were exchanged, compared to its average volume of 444,186. The company has a quick ratio of 1.56, a current ratio of 2.44 and a debt-to-equity ratio of 1.30. Natera has a 52-week low of $8.60 and a 52-week high of $29.62. The firm has a market cap of $969.32 million, a P/E ratio of -6.70 and a beta of 2.11.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: How Do Tariffs Affect Trade Balances?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.